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SUMMARY 
 
   Forty patients with spinal cord gliomas,  irradiated postoperatively between 1976 and 1994 
at the Department of Radiation Oncology of Maria Skłodowska-Curie Memorial Centre in Kraków, 
were retrospectively reviewed. Twenty seven (67%) patients were classified as those with ependy-
momas, and 13 (33%) with astrocytomas. Thirty six patients were irradiated because of non radical 
excision, in 4 cases indication for radiotherapy was high grade histology. The overall actuarial survival 
rates at 5 and 10-years were 74% and 71%, respectively. The 10-year relapse free survival was 69%. 
Multivariate analysis showed that only age, histology and neurological function were correlated with 
survival time. Patients under 30 years of age, with ependymoma, and with very good, good or mode-
rate neurological function carried the best prognosis.  
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INTRODUCTION 
 
   Primary tumours of the spinal cord are 
rare and account for about 7% of adult 
central nervous system neoplasms [1,2]. 
Gliomas occur in 22% of all primary spinal 
tumours, of these 63% are ependymomas, 
25% are astrocytomas and 7% are glio-
blastomas [3].  
   The management of spinal cord glioma 
is still unclear. The treatment of choice 
is surgical resection with preservation 
of neurologic function. [4-8]. Because 
of their infiltrative nature, the excision 
of spinal glioma can be difficult to achieve. 
Complete surgical resection is potentially 
curative. It is generally accepted that 
postoperative irradiation is suggested 
when macroscopic or microscopic residual 
tumour persists [3,9-18]. The radiosensi-
tivity of the spinal cord limits the dose 
of radiation that can be given to the tu-
mour. Most authors recommend a dose 
of 45-55 Gy delivered with conventional 
fraction doses. For patients with high gra-
de gliomas, localised at the level of tho-
racic or lumbar spinal cord, who have 
permanent transverse meyolopathy appli-
cation of doses higher or equal 60 Gy, has 
also been an option [18,19].  
 
MATERIAL AND METHODS 
 
   Records of 40 patients with spinal cord 
gliomas, irradiated postoperatively be-
tween 1976 and 1994 at the Department 
of Radiation Oncology of Maria Skłodo-
wska-Curie Memorial Centre in Kraków, 
were retrospectively reviewed. The para-
meter monitored to determine clinical res-
ponse to therapy was neurological function 
(according to Shirato scale – Tab. 1) [18].  
 
Tab. 1. Classification of neurological functions according 
to Shirato [18]. 
 
Assessment Neurological function 
Excellent Intact or minimal neurological deficit,
no functional impairment 
Good Mild neurological deficit, ambulating 
without braces or aids, no functional 
impairment 
Fair Moderate neurological deficit, ambu-
lating with braces and/or aids, 
significant functional impairment 
Poor Quadriplegic or paraplegic, wheelchair 
dependent, significant functional 
impairment  
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   There were 16 female (40%) and 
24 male (60%) patients with a median age 
of 33 years (range: 16-57). Pain was 
the most common presenting symptom 
at pretreatment examination, followed 
by motor weakness, sensory loss and 
sphincter dysfunction. The median length 
of symptoms, prior to diagnosis, was 36 
months (range: 1 month to 150 months). 
Initial radiological investigation consisted 
of myelogram alone in 34 cases (85%), 
myelogram and CT in 2 cases (5%), CT 
in 2 cases (5%) and MRI in 2 cases (5%). 
The distribution of sites of involvement 
was as follows: cervical spinal cord - 2 pa-
tients (5%), thoracic - 11 patients (32%) 
and cauda equina - 21 patients (34%). 
In 6 patients (15%), a multifocal spinal 
disease was observed. All patients under-
went surgical resection aimed at removing 
as much tumoral tissue as possible with 
preservation of neurologic function. Thirty 
five surgical resections (88%) were consi-
dered as subtotal, 4 (10%) as gross total 
resection and 1 (2%) as biopsy alone. 
The distribution of histologic types 
in the group studied was as follows: 
27 ependymomas (67%), 13 astrocytomas 
(33%). In 33 (82.5%) cases histology 
grade was available. 
   Before radiotherapy, performance status 
and neurological function were assessed. 
Karnofsky’s score was superior or equal 
to 80% in 6 cases (15%), 70%-50% 
in 32 cases (80%) and 40% or less 
in 2 cases (4%). Neurologic function was 
assessed as very good in 3 patients (8%), 
good in 12 patients (30%), moderate 
in 14 patients (35%) and poor in 11 pa-
tients (27%) 
   All patients were treated with mega-
voltage external beam radiotherapy, ener-
gies used including cobalt (1.25 MV) and 
9 MV photons. Thirty six patients were 
irradiated because of non radical excision; 
in 4 cases indication for radiotherapy was 
high grade histology. The total dose ran-
ged from 24 to 75 Gy (mean: 51.13 Gy), 
delivered with daily fractions of 1.5-6 Gy 
(Tab. 2). The direct posterior field in 36 pa-
tients (90%) or posterior oblique fields with 
wedges in 4 patients (10%) were used. 
The treatment volume covered the resi-
dual tumour or the site of the tumour 
removal with a margin of 3 cm. Doses 
above 55 Gy were used in patients who 
already had poor motor function status, 
with tumour location in the thoracic or lum-
bar spinal cord. In those cases no de-
terioration of neurological function was 
apparent.  
 
Tab. 2. Range of total and fraction doses in the analysed 
group. 
 
Total dose Fraction dose 
No 
of patients % 
25 – 45 Gy 2.5 - 6 Gy 8 20 
>45 – 55 Gy 1.5 – 3 Gy 22 55 
>55 Gy 2 – 3 Gy 10 25 
 
   Survival was measured from the first day 
of radiotherapy. The survival was 
estimated by the Kaplan-Meier method 
[20]. Prognostic factor analysis included 
univariate and multivariate analysis. 
The Kaplan-Meier method and log rank 
test were used for univariate analysis; 
the Cox regression model was used 
for multivariate analysis [21,22]. 
 
RESULTS 
 
   The treatment was generally well 
tolerated. All patients completed their 
course of radiation therapy. 
   After radiotherapy, 23 patients (58%) 
showed improvement in neurological fun-
ction, in 15 cases (37%) neurological fun-
ction was assessed as steady. In 2 (5%) 
cases neurological function became worse 
due to progression of the tumour. 
 
Survival 
 
   The overall actuarial survival rates 
at 5 and 10-years were 74% and 71%, 
respectively (Fig. 1). The 10-year relapse 
free survival was 69% (Fig. 2). 
   The following characteristics were asso-
ciated with improved patient survival by 
univariate analysis: age <=30; very good, 
good and moderate neurological function 
before radiotherapy; ependymoma histo-
logy; and tumour location in cauda equina 
(test log rank p<=0.05, Figs. 3-6). Gender 
and total dose had no influence on pro-
gnosis. There was no assessment of tu-
mour grade due to small subgroups. 
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Results of univariate analysis of prognostic 
factors are presented in Tab. 3. Multi-
variate analysis showed that only age, 
histology and neurological function were 
correlated with the survival time. Patients 
under 30 years of age, with ependymoma, 
and with very good, good or moderate 
neurological function carried the best pro-
gnosis.  The definitive results of the Cox 
model are given in Tab. 4. 
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Fig. 1. Overall survival of 40 postoperatively irradiated patients with  spinal cord gliomas.  
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Fig. 2. Relapse free survival of 40 postoperatively irradiated patients with spinal cord gliomas.  
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Fig. 3. Overall survival of 40 postoperatively irradiated patients with spinal cord gliomas according to age.
p = 0.3453
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Fig. 4. Overall survival of 40 postoperatively irradiated patients with spinal cord gliomas according to histology.  
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Fig. 5. Overall survival of 40 postoperatively irradiated patients with spinal cord gliomas according to neurological function 
(Shirato scale).
neur. function 1,2,3  very good, good, moderate neurological function
neur. function 4  poor neurological function  
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Fig. 6. Overall survival of 40 postoperatively irradiated patients with spinal cord gliomas according to  localisation.
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Tab. 3. Univariate analysis of prognostic factors in 40 patients with spinal cord glioma. 
 
Factors Relative                 p  
risk 
Actuarial                      p 
10-year survival 
Age  
<=30 n=18 
>30 n=22 
 
1.00 - 
8.13                   0.011413 
 
82% 0.03453 
61% 
Gender 
male n=24 
female n=16 
 
1.00 - 
1.07                   0.894151 
 
75% 0.89432 
65%  
Neurological function  
very good, good, moderate n=29 
poor n=11 
 
1.00 - 
4.14                   0.024456 
  
82% 
42% 0.00474 
Localisation 
cauda equina n=21 
others  n=19 
 
1.0 - 
3.67                   0.028589 
 
84% 
55% 0.01942 
Histology  
ependymoma n=27 
astrocytoma n=13 
 
1.00 - 
3.01                   0.041276 
 
84% 
46% 0.04439 
Total dose 
>45 Gy  n=32 
<= 45 Gy n=8 
 
1.0 - 
2.01                   0.212003 
 
78% 
50% 0.18279 
 
Tab. 4. The definitive Cox model in 40 patients with spinal cord glioma. 
 
Factor Relative risk P-value Confidence interval 
Histology  
ependymoma    
astrocytoma    
 
1.00 
8.65 
  
- 
0.002761 
 
2.11-35.53 
Age  
<=30   
>30     
 
1.00 
8.13 
 
- 
0.011413 
 
1.60-41.30 
Neurological function  
very good, good, moderate   
poor 
 
1.00 
4.14 
 
- 
0.024456 
 
1.20-14.28 
 
 
Recurrences 
 
   Clinical progression was observed 
in 15 patients (37%), in all cases the fai-
lure was observed at the primary site. 
In 3 cases it was documented by myelo-
gram, in 4 cases by CT, in one case 
by MRI and in 7 cases assessed only 
by neurological examination. The median 
time to recurrence was 20 months (range: 
1-217 months). Four patients underwent 
second operation, one combined therapy - 
surgery and chemotherapy and one - 
chemotherapy. Nine patients received only 
symptomatic treatment. 
 
DISCUSSION 
 
   Numerous prognostic factors have been 
reported in spinal cord gliomas such as 
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age, performance status, neurological fun-
ction, length of symptoms, tumour histo-
logy, grade, location and stage.  
   Our results indicate that histology and 
age are the principal variables determining 
the survival of patients with spinal cord 
gliomas.  
   The actuarial 10-year survival rates were 
84% and 46% respectively, in patients 
with ependymoma and astrocytoma 
(p=0.04439). Patients with low grade 
ependymoma have an excellent survival 
rate, while patients with astrocytoma, even 
of low grade, have a less favourable 
outcome. These findings agree with many 
other reports [9-11,18,23-25]. Shirato et al 
present 5-year actuarial survival rates 
in ependymal tumour and those in astro-
cytic tumour 96% and 50%, respectively 
(p=0.007) [18]. 
   The actuarial 10-year survival rates were 
82% and 61%, respectively, in patients 
aged 30 or under and those over 30 
(p=0.03453). In the series of 52 patients 
with spinal cord gliomas reported by Rodri-
ges et al., 5-year cause-specific survival 
rates were, respectively, 100% in patients 
aged 18 or under compared to 56% 
in patients over 18 (p=0.03) [3]. Huddart 
et al. found 5-year overall survivals 
of 80%, 64% and 38% in patients under 
16, those between  16 and 39, and those 
over 40, respectively (borderline statistical 
significance p<0.10) [26]. On the other 
hand, there are a few reports which did not 
find differences in the survival rates 
depending on age [16,17,24].  
    Also the parameters of neurological 
state showed prognostic influence on 
the survival in the multivariate analysis 
of our series. The actuarial 10-year sur-
vival rate was 82% in patients with very 
good, good and moderate neurological 
function and 42% in patients with poor 
neurological function (p=0.00474). These 
findings agree with other reports [23,27]. 
Neurological function is directly connected 
with stage and length of the disease, and 
tumour location. Neurological status is 
better in patients with a low stage disease 
and those with tumour located in the cau-
da equina. Duration of symptoms is shor-
ter in this group compared to patients with 
poorer neurological function, which allows 
recovery of neurological function after 
treatment. An attempt has been made 
to explain the favourable prognosis 
in younger patients with good neurological 
function by better tolerance of treatment: 
surgery as well as radiotherapy.  
   In our material, univariate analysis 
showed that tumour location was a sta-
tistically significant prognostic indicator. 
The actuarial 10-year survival rates were 
84% and 55%, respectively, in patients 
with tumour of cauda equina and other 
sites (p=0.01942). This is consistent with 
the study of Garcia who found that 
patients with tumours of cauda equina had 
significantly better survival than those with 
tumours at other locations [9]. Explanation 
for this observation includes greater 
concentration of function per unit volume 
of the spinal cord in comparison with 
cauda equina.  
   In the presented series, gender had no 
influence on prognosis, which is in agree-
ment with  the results of Rodrigues et al. 
[3]. However, some authors have obser-
ved that female patients have statistically 
significant survival advantage over male 
patients [24,26].  
   The treatment of choice for spinal cord 
glioma is surgery. After radical excision 
postoperative radiotherapy is not indicated 
because of a low local recurrence rate 
[4,5,7,8]. Complete resection should not 
be attempted however, if more extensive 
surgical excision would result in unaccep-
table neurologic deficit. With modern 
surgical techniques, ependymomas are 
relatively easy to excise completely 
[5,25,28]. Total resection of astrocytoma 
is usually difficult because its margin from 
the normal spinal cord is poorly defined 
as compared with ependymoma. The ex-
tent of surgery does not influence signi-
ficantly the survival of patients with astro-
cytic spinal cord tumours [3,8,10,12,23]. 
   Combined surgery and postoperative 
radiotherapy in patients with spinal cord 
glioma make it possible to obtain long-
term survival. Review of the literature 
confirms that postoperative irradiation 
is beneficial in patients with biopsied 
or subtotally excised spinal cord glioma 
[3,9-18,25,26]. The doses required 
for the optimal management of spinal cord 
gliomas are not well established due 
to the rarity of this tumour type. Most 
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authors recommend doses of 45-50 Gy, 
conventionally fractionated. In the series 
presented by Cohen and Shirato, some 
patients received a total dose of 60 Gy 
and higher, but because of the small 
number of patients no dose response 
relationship to establish a control rate has 
been recorded [18,19]. The patients 
treated in this way had a high grade 
glioma at the level of the thoracic or lum-
bar spinal cord and already showed per-
manent poor motor function. 
   In the present series no significant 
differences in the survival retes were 
found in patients who were treated with 
a dose lower than 45 Gy, when compared 
with those treated with 45 Gy or more. 
This is consistent with most of the public-
shed results. It should be noted, however, 
that interpretation of dose response data 
in small retrospective series is not reliable.  
   The high incidence of local failure, des-
pite total dose in the range of 45-50 Gy, 
indicates a need for more effective the-
rapy. Strategies to increase dose delivered 
with acceptable levels of late toxicity 
should be investigated. Hyperfractionated 
irradiation for spinal cord tumours offers 
the ability to elevate total dose and 
maintain the same level of late effects. 
The use of novel radiotherapy techniques 
such as: 3-D treatment planning, dynamic 
conformal RT, and stereotactic RT might 
improve local control. The systemic the-
rapy can also be considered in patients 
with high-grade tumours. It is possible that 
combination of radiotherapy and chemo-
therapy in this group will result in more 
favourable outcomes.   
 
CONCLUSION 
 
1. Combined surgery and postoperative 
radiotherapy in patients with spinal 
cord glioma result in 5-year and 
10-year overall actuarial survival rates 
in 74% and 71% of cases, respe-
ctively.  
2. Age, histology (astrocytoma vs. epen-
dymoma) and neurological function 
before radiotherapy were significant 
variables determining the survival 
of patients with spinal cord glioma. 
Patients under 30 years of age, with 
ependymoma, and with very good, 
good or moderate neurological function 
carried the best prognosis. 
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